company background image
NAMS logo

NewAmsterdam Pharma NasdaqGM:NAMS Stock Report

Last Price

US$22.70

Market Cap

US$2.0b

7D

2.5%

1Y

69.9%

Updated

27 Mar, 2024

Data

Company Financials +

NewAmsterdam Pharma Company N.V.

NasdaqGM:NAMS Stock Report

Market Cap: US$2.0b

NAMS Stock Overview

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease.

NAMS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NewAmsterdam Pharma Company N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NewAmsterdam Pharma
Historical stock prices
Current Share PriceUS$22.70
52 Week HighUS$26.35
52 Week LowUS$5.63
Beta0.021
1 Month Change2.90%
3 Month Change98.60%
1 Year Change69.91%
3 Year Change127.91%
5 Year Changen/a
Change since IPO110.19%

Recent News & Updates

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 03
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Recent updates

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 03
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Shareholder Returns

NAMSUS BiotechsUS Market
7D2.5%-0.5%0.6%
1Y69.9%9.6%29.5%

Return vs Industry: NAMS exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: NAMS exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is NAMS's price volatile compared to industry and market?
NAMS volatility
NAMS Average Weekly Movement14.6%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: NAMS's share price has been volatile over the past 3 months.

Volatility Over Time: NAMS's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a29Michael Davidsonhttps://www.newamsterdampharma.com

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, an oral and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V. Fundamentals Summary

How do NewAmsterdam Pharma's earnings and revenue compare to its market cap?
NAMS fundamental statistics
Market capUS$2.03b
Earnings (TTM)-US$176.94m
Revenue (TTM)US$14.09m

143.8x

P/S Ratio

-11.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NAMS income statement (TTM)
RevenueUS$14.09m
Cost of RevenueUS$0
Gross ProfitUS$14.09m
Other ExpensesUS$191.03m
Earnings-US$176.94m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.98
Gross Margin100.00%
Net Profit Margin-1,255.76%
Debt/Equity Ratio0%

How did NAMS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.